Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
First Claim
1. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a composition comprising a population of activated T cells that selectively recognize the cancer cells that present a peptide consisting of the amino acid sequence of ALLTFVWKL (SEQ ID NO:
- 4),wherein the activated T cells are produced by contacting T cells with the peptide loaded human class I or II MHC molecules expressed on the surface of an antigen-presenting cell for a period of time sufficient to activate the T cells,wherein said cancer is selected from the group consisting of prostate cancer, lung cancer, small cell lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon or rectum cancer (CRC), urinary bladder cancer, non-small cell lung cancer, kidney cancer, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), ovarian cancer, esophageal cancer, brain cancer, and gastric (stomach) cancer.
1 Assignment
0 Petitions
Accused Products
Abstract
A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.
4 Citations
20 Claims
-
1. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a composition comprising a population of activated T cells that selectively recognize the cancer cells that present a peptide consisting of the amino acid sequence of ALLTFVWKL (SEQ ID NO:
- 4),
wherein the activated T cells are produced by contacting T cells with the peptide loaded human class I or II MHC molecules expressed on the surface of an antigen-presenting cell for a period of time sufficient to activate the T cells, wherein said cancer is selected from the group consisting of prostate cancer, lung cancer, small cell lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon or rectum cancer (CRC), urinary bladder cancer, non-small cell lung cancer, kidney cancer, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), ovarian cancer, esophageal cancer, brain cancer, and gastric (stomach) cancer. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
- 4),
-
18. A method of eliciting an immune response in a patient who has prostate cancer, lung cancer, small cell lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon or rectum cancer (CRC), urinary bladder cancer, non-small cell lung cancer, kidney cancer, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), ovarian cancer, esophageal cancer, brain cancer, or gastric (stomach) cancer, comprising administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, wherein said peptide consists of the amino acid sequence of ALLTFVWKL (SEQ ID NO:
- 4), thereby inducing a T cell response to the prostate cancer, lung cancer, small cell lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon or rectum cancer (CRC), urinary bladder cancer, non-small cell lung cancer, kidney cancer, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), ovarian cancer, esophageal cancer, brain cancer, or gastric (stomach) cancer.
- View Dependent Claims (19, 20)
Specification